• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 10, 2018

View Archived Issues

Novartis makes $8.7B play for gene therapy developer Avexis

Less than a year after landing the first gene therapy approval in the U.S. and just months after licensing certain rights to another, Novartis AG is making yet further bets on the field with an $8.7 billion offer to buy Chicago-based Avexis Inc., a company developing a gene therapy for spinal muscular atrophy (SMA). Read More

Regulatory actions for April 9, 2018

Read More

Menlo can't stop the indication expansion itch

Despite two positive phase II trials showing serlopitant helped patients with pruritus –itchy skin – Menlo Therapeutics Inc. couldn't go three for three at the proof-of-concept plate, failing to show an effect on pruritus in patients with a history of atopic dermatitis. Read More

Infinity pool: Water's fine, Verastem swimming near approval for PI3K therapy

Verastem Inc. CEO Robert Forrester told BioWorld that the company seeks to share the upper atmosphere's "rarefied air" with small-to-mid cap biotechs that have reached the market with new oncology drugs to fly the same skies as big pharma. "These things don't happen very often," he noted. "If we are fortunate, we will be the 11th" such smaller firm since 2010 to win clearance for a promising cancer compound. Read More

AMO Pharma advancing ultra-rare program on back of phase IIb data

LONDON – AMO Pharma Ltd. is laying plans, both clinical and financial, for a phase III study of its lead program, AMO-02 (tideglusib), after reporting final data from a phase IIb proof-of-concept trial in the treatment of congenital and childhood onset myotonic dystrophy type 1. Read More

U.S. drugmakers might be on the losing end in trade war with China

HONG KONG – The Trump administration has proposed placing a 25 percent tariff on more than 1,300 imported goods from China, such as biotech materials and medical devices, a move some say could eventually hurt U.S. drugmakers. Read More

Therapix rises on phase II Tourette syndrome study

Shares of Therapix Biosciences Ltd. gained 24 percent Monday on top-line results from a phase IIa study showing that THX-110 significantly improved symptoms over time in adults with Tourette syndrome. The Tel Aviv, Israel-based firm plans to launch a larger, randomized, double-blind trial to test the cannabinoid product, which combines dronabinol and palmitoylethanolamide. Read More

Financings

Rxi Pharmaceuticals Corp., of Marlborough, Mass., entered agreements with investors for the purchase of about 1.5 million shares of common stock at $3.24375 apiece for gross proceeds of about $4.9 million in a registered direct offering priced at the market.  Read More

Regulatory front

U.S. Rep. Frank Pallone (D-N.J.), ranking member of the House Energy and Commerce Committee, is taking the Centers for Medicare & Medicaid Services (CMS) to task for not updating its drug spending dashboards since Donald Trump became president.  Read More

Other news to note

Ionis Pharmaceuticals Inc., of Carlsbad, Calif., said it licensed IONIS-AZ6-2.5-LRx, or AZD-2693, to Cambridge, U.K.-based Astrazeneca plc now that the drug has advanced into development.  Read More

Clinical data for April 9, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 24, 2025.
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

    Otsuka licenses Harbour’s bispecific T-cell engager for $670M

    BioWorld
    Harbour Biomed is out-licensing its B-cell maturation antigen and CD3 bispecific T-cell engager HBM-7020 for autoimmune diseases to Otsuka Pharmaceutical Co. Ltd....
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe